Lipid lowering: statins and the future.
نویسنده
چکیده
Cardiovascular disease (CVD) is the leading cause of death in developed and many developing countries. Between 1970 and 1992 there has been a slow decline in some areas, notably North America, Western Europe, Australia, and New Zealand. However, CVD mortality has recently increased in Eastern and Central Europe. A whole spectrum of therapeutic tools is available to manage CVD including thrombolytics, antiplatelet drugs, â blockers, angiotensin converting enzyme (ACE) inhibitors, and statins. By using these drugs singly or in combination, CVD risk can be reduced by as much as 50%.
منابع مشابه
Statins: Newer Roles Including Lipid Lowering Therapy
Statins are most effective pharmacologically agents to decrease total plasma cholesterol level by competitive inhibition of HMG-Co A reductase. Apart from the well-known LDL and cholesterol lowering effect, statins have been postulated to exert other beneficial effects also called pleotropic or non-lipid effects. Better understanding of various pleotropic effects of statins has prompted a new s...
متن کاملCarvedilol: A Promising Drug Combined with Lipid-lowering Medications for Patients with Hypertension and Heart Failure
Background: Statins frequently cause myopathy especially in combination with fibrates, and physical activity is considered a trigger for the muscle disorder. Elevated plasma levels of creatine kinase (CK), lactate dehydrogenase (LDH) and aldolase, are the main indicators of the severity of myopathy. Carvedilol is commonly used with lipid-lowering drugs in the management of heart failure, hypert...
متن کاملDespite Affordability, Low Utilization of Lipid Lowering Drugs in Iran: Trend Analysis and Benchmarking 2005-2016
Dyslipidemia is responsible for great mortality and morbidity each year. Little data are available on the availability and affordability of Dyslipidemia medications in low and middle incomes countries. In a retrospective time-series study, we examined the utilization pattern and affordability of lipid-lowering medications in Iran as a lower middle-income country. We initially calculated the def...
متن کاملDespite Affordability, Low Utilization of Lipid Lowering Drugs in Iran: Trend Analysis and Benchmarking 2005-2016
Dyslipidemia is responsible for great mortality and morbidity each year. Little data are available on the availability and affordability of Dyslipidemia medications in low and middle incomes countries. In a retrospective time-series study, we examined the utilization pattern and affordability of lipid-lowering medications in Iran as a lower middle-income country. We initially calculated the def...
متن کاملBeyond lipid-lowering therapy: does ezetimibe enhance the effects of statins on atherosclerosis?
Given the close relationship between serum cholesterol and cardiovascular risk, it is unsurprising that lipid-lowering therapy has been shown to markedly reduce cardiovascular events in various studies of diverse populations at cardiovascular risk [1–3]. There is up to a 19% reduction in cardiovascular events for every 1.0-mmol reduction in the level of low-density-lipoprotein cholesterol (LDL-...
متن کاملMeta-Analysis of the SLCO1B1 c.521T>C Variant Reveals Slight Influence on the Lipid-Lowering Efficacy of Statins
BACKGROUND Several studies have focused on the association between the lipid-lowering efficacy of statins and the SLCO1B1 c.521T>C polymorphism; however, the results are conflicting. The effects of statins show significant variability between individuals. This meta-analysis aimed to investigate the effects of the SLCO1B1 c.521T>C polymorphism on the lipid-lowering effects of statins. METHODS ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Heart
دوره 84 Suppl 1 شماره
صفحات -
تاریخ انتشار 2000